Infliximab antibody | AbD19376_hIgG1
To confirm antibody specificity, a microtiter plate was coated overnight with various antigens at a concentration of 5μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated HCA216P at 2μg/ml, in HISPEC assay diluent (BUF049A) and QuantaBlu fluorogenic peroxidase substrate.
To assess the ability of HCA216 to inhibit the binding of Infliximab to its target molecule, a microtiter plate was coated overnight with HCA216 (as Fab fragment) at 5.0 μg/mL. After washing and blocking with PBST+5% BSA, Infliximab alone (red circles), or with 5.0 fold molar excess of TNF-α (black squares) was added in the given concentrations. Free or TNF-α bound Infliximab binding to HCA216 was detected using Mouse anti Human IgG (Fc) CH2 domain:HRP (MCA647P).
A microtiter plate was coated overnight with HCA214 at a concentration of 1μg/ml. After washing and blocking with PBST+5% BSA, Infliximab spiked in 10% human serum was added at the given concentrations. Detection was performed using HRP-conjugated HCA216 at 2μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu fluorogenic peroxidase substrate.
A microtiter plate was coated overnight with HCA212 at a concentration of 5μg/ml. After washing and blocking with PBST+5% BSA, Infliximab spiked in 10% human serum was added at the given concentrations. Detection was performed using HRP-conjugated HCA216 at 2μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu fluorogenic peroxidase substrate.
A microtiter plate was coated overnight with Infliximab at a concentration of 1μg/ml. After washing and blocking with PBST+5% BSA, anti Infliximab HCA216 spiked in 10% human serum was added at the given concentrations. Detection was performed using HRP-conjugated Infliximab.
Human anti Infliximab
- Product Type
- Monoclonal Antibody
- Clone
- AbD19376_hIgG1
- Isotype
- IgG1
- Specificity
- Infliximab
Antibody Quality and Performance Guarantee
| Human anti Infliximab, clone AbD19376_hIgG1, is an anti-idiotypic antibody that binds to both free infliximab and to infliximab bound to its target, TNFα. Clone AbD19376_hIgG1 does not inhibit the binding of infliximab to TNFα. It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples. Clone AbD19376_hIgG1 binds to an epitope outside the infliximab binding site. This epitope is shared with other chimeric antibodies that are highly homologous to infliximab including the chimeric antibody cetuximab but not rituximab. Human anti Infliximab, clone AbD19376_hIgG1 is a fully human antibody and may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera. In the HRP-conjugated format, clone AbD19376_IgG1 is suitable as a detection antibody in pharmacokinetic (PK) assays to measure total infliximab levels (free drug, partially bound and fully bound). Infliximab (branded as Remicade®) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab is directed against Tumor Necrosis Factor Alpha (TNFα) and acts by blocking the binding of this cytokine to its receptors. Infliximab also induces apoptosis of TNFα expressing T-lymphocytes. View a summary of all anti-infliximab antibodies. |
|
- Product Form
- Human IgG1 antibody selected from the HuCAL phage display library and expressed in a human cell line.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A.
- Source
- HKB-11
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Immunogen
- Infliximab
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD=0.7 nM by real time, label-free molecular interaction analysis on immobilized inifliximab.
- Approx. Protein Concentrations
- Antibody concentration 0.5 mg/ml.
- Regulatory
- For research purposes only.
- Guarantee
- 12 months from date of despatch.
- Acknowledgements
- This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Remicade is a registered trademark of Janssen Biotech Inc. Inflectra is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS is a trademark of Merck Sharp & Dohme Corp. - Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |  |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in a direct ELISA, as a bridging antibody in ADA assays or as a detection antibody in an Infliximab bridging ELISA when conjugated to HRP together with HCA212 or HCA214 as the capture reagent.
Protocol: PK bridging ELISA to measure total drug
Protocol: ADA bridging ELISA
| Description | Product Code | Applications | Pack Size | List Price | Your Price | Quantity | |
|---|---|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Hispec Assay Diluent | ||||||
| Human anti Infliximab | HCA212 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Human anti Infliximab | ||||||
| Human anti Infliximab | HCA213 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Human anti Infliximab | ||||||
| Human anti Infliximab | HCA214 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Human anti Infliximab | ||||||
| Human anti Infliximab | HCA215 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Human anti Infliximab | ||||||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | LYNX Rapid HRP Antibody Conjugation Kit | ||||||
| Mouse anti Human IgG (Fc) CH2 Domain:HRP | MCA647P | C * E | 0.2 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Mouse anti Human IgG (Fc) CH2 Domain:HRP | ||||||
| Recombinant Human TNF Alpha | PHP051 | E FN WB | 50 µg | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Recombinant Human TNF Alpha | ||||||
References for Infliximab antibody
-
Kashiwagi, N. et al. (0) Method for measuring anti-drug antibody
US Patent Application US2017315118A1
- Synonyms
- REMICADE®
View more products with INFLIXIMAB specificity
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up